MENS
Jyong Biotech Ltd. Ordinary Shares
Biotechnology
Market Cap$160M
5Y Perf.-74.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MENS vs AEYE
Revenue, margins, valuation, and 5-year total return — side by side.
AEYE
AudioEye, Inc.
Software - Application
Market Cap$95M
5Y Perf.-34.2%
MENS vs AEYE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MENS | AEYE |
|---|---|---|
| Industry | Biotechnology | Software - Application |
| Market Cap | $160M | $95M |
| Revenue (TTM) | $0.00 | $40M |
| Net Income (TTM) | $-3K | $-3M |
| Gross Margin | — | 78.3% |
| Operating Margin | — | -7.9% |
| Total Debt | $18M | $721K |
| Cash & Equiv. | $98K | $5M |
MENS vs AEYE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MENS
AEYE
| Stock | Jun 25 | May 26 | Return |
|---|---|---|---|
| Jyong Biotech Ltd. … (MENS) | 100 | 25.3 | -74.7% |
| AudioEye, Inc. (AEYE) | 100 | 65.8 | -34.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MENS vs AEYE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AEYE leads in 3 of 5 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Jyong Biotech Ltd. Ordinary Shares is the stronger pick specifically for operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MENS
Jyong Biotech Ltd. Ordinary Shares
The Growth Play
MENS is the clearest fit if your priority is growth exposure.
- EPS growth 31.4%
- -0.0% ROA vs AEYE's -9.5%
Best for: growth exposure
AEYE
AudioEye, Inc.
The Income Pick
AEYE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 2.29
- 80.2% 10Y total return vs MENS's -78.7%
- Lower volatility, beta 2.29, Low D/E 15.0%, current ratio 0.88x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | AEYE | -7.6% margin vs MENS's -16.1% |
| Stability / Safety | AEYE | Beta 2.29 vs MENS's 2.49 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AEYE | -35.7% vs MENS's -78.7% |
| Efficiency (ROA) | MENS | -0.0% ROA vs AEYE's -9.5% |
MENS vs AEYE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MENS vs AEYE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAEYELAGGINGMENS
MENSJyong Biotech Ltd. Or…
2leads
AEYEAudioEye, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs MENSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MENS1/1
Valuation MetricsMultiples, price ratios, and targets
MENS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AEYE4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
AEYE6/6
Risk & VolatilityBeta, volatility, and downside exposure
AEYE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MENS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AEYE and MENS operate at a comparable scale, with $40M and $0 in trailing revenue.
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $40M |
| EBITDAEarnings before interest/tax | -$1,936 | -$504,000 |
| Net IncomeAfter-tax profit | -$3,019 | -$3M |
| Free Cash FlowCash after capex | -$3,624 | $2M |
| Gross MarginGross profit ÷ Revenue | — | +78.3% |
| Operating MarginEBIT ÷ Revenue | — | -7.9% |
| Net MarginNet income ÷ Revenue | — | -7.6% |
| FCF MarginFCF ÷ Revenue | — | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.6% | +29.0% |
MENS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
MENS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| Market CapShares × price | $160M | $95M |
| Enterprise ValueMkt cap + debt − cash | $178M | $91M |
| Trailing P/EPrice ÷ TTM EPS | -54.16x | -30.64x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.36x |
| Price / BookPrice ÷ Book value/share | — | 19.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
MENS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
AEYE leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), AEYE scores 4/9 vs MENS's 2/9, reflecting mixed financial health.
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | — | -47.8% |
| ROA (TTM)Return on assets | -0.0% | -9.5% |
| ROICReturn on invested capital | — | -42.4% |
| ROCEReturn on capital employed | — | -17.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.15x |
| Net DebtTotal debt minus cash | $18M | -$5M |
| Cash & Equiv.Liquid assets | $98,000 | $5M |
| Total DebtShort + long-term debt | $18M | $721,000 |
| Interest CoverageEBIT ÷ Interest expense | -4.00x | -2.79x |
AEYE leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
AEYE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AEYE five years ago would be worth $3,632 today (with dividends reinvested), compared to $2,127 for MENS. Over the past 12 months, AEYE leads with a -35.7% total return vs MENS's -78.7%. The 3-year compound annual growth rate (CAGR) favors AEYE at 4.5% vs MENS's -40.3% — a key indicator of consistent wealth creation.
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -37.0% | -23.0% |
| 1-Year ReturnPast 12 months | -78.7% | -35.7% |
| 3-Year ReturnCumulative with dividends | -78.7% | +14.2% |
| 5-Year ReturnCumulative with dividends | -78.7% | -63.7% |
| 10-Year ReturnCumulative with dividends | -78.7% | +80.2% |
| CAGR (3Y)Annualised 3-year return | -40.3% | +4.5% |
AEYE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
AEYE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AEYE is the less volatile stock with a 2.29 beta — it tends to amplify market swings less than MENS's 2.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AEYE currently trades 46.7% from its 52-week high vs MENS's 3.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.49x | 2.29x |
| 52-Week HighHighest price in past year | $67.00 | $16.39 |
| 52-Week LowLowest price in past year | $1.43 | $5.31 |
| % of 52W HighCurrent price vs 52-week peak | +3.2% | +46.7% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 59.7 |
| Avg Volume (50D)Average daily shares traded | 157K | 194K |
AEYE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MENSJyong Biotech Ltd… | AEYEAudioEye, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AEYE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). MENS leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallAudioEye, Inc. (AEYE)Leads 3 of 6 categories
Loading custom metrics...
MENS vs AEYE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — MENS or AEYE?
Over the past 5 years, AudioEye, Inc.
(AEYE) delivered a total return of -63. 7%, compared to -78. 7% for Jyong Biotech Ltd. Ordinary Shares (MENS). Over 10 years, the gap is even starker: AEYE returned +80. 2% versus MENS's -78. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — MENS or AEYE?
By beta (market sensitivity over 5 years), AudioEye, Inc.
(AEYE) is the lower-risk stock at 2. 29β versus Jyong Biotech Ltd. Ordinary Shares's 2. 49β — meaning MENS is approximately 9% more volatile than AEYE relative to the S&P 500.
03Which is growing faster — MENS or AEYE?
On earnings-per-share growth, the picture is similar: Jyong Biotech Ltd.
Ordinary Shares grew EPS 31. 4% year-over-year, compared to 30. 6% for AudioEye, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — MENS or AEYE?
Jyong Biotech Ltd.
Ordinary Shares (MENS) is the more profitable company, earning 0. 0% net margin versus -7. 6% for AudioEye, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MENS leads at 0. 0% versus -7. 9% for AEYE. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MENS or AEYE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MENS or AEYE better for a retirement portfolio?
For long-horizon retirement investors, AudioEye, Inc.
(AEYE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Jyong Biotech Ltd. Ordinary Shares (MENS) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AEYE: +80. 2%, MENS: -78. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MENS and AEYE?
These companies operate in different sectors (MENS (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.